Appeals court upholds judgment in favor of Allergan in suit with Teva, Sandoz

theflyonthewall.com

The U.S. Appeals Court for the Federal Circuit affirmed a lower court ruling that proposed products described in Abbreviated New Drug Applications from Teva Pharmaceuticals (TEVA) and Sandoz, a unit of Novartis (NVS), infringed claim 10 of Allergan's (AGN) ’819 patent for Lumigan. Lumigan is FDA approved to reduce intraocular pressure in people with ocular hypertension or glaucoma.

View Comments (0)